Strategies for Managing DOAC-Associated Bleeding
This CME/CNE/CPE-accredited program will be tailored to “on-the-ground” clinicians who make critical treatment decisions for patients with significant bleeds while on a DOAC.
Target Audience
The intended audience for this program will consist of Physicians, Nurse Practitioners, Physician Assistants, Nurses, and Pharmacists in the fields of Emergency Medicine, Critical Care, and Neurocritical Care.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Describe factors that drive bleeding risk in patients on DOACs.
- Determine when to use DOAC reversal agents.
- Assess the balance of bleeding and thrombotic risk in patients taking DOACs.
- Recognize the importance of restarting DOAC therapy after a bleed.
- Identify systems-based approaches to standardizing anticoagulation reversal management.
Conflicts of Interest Disclosure Policy:
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.
FACULTY AND DISCLOSURES
Faculty
Allison E. Burnett, PharmD, PhC, CACP
Antithrombosis Stewardship
University of New Mexico Hospital
Albuquerque, New Mexico
Margaret C. Fang, MD, MPH
Professor of Medicine
The University of California, San Francisco
San Francisco, California
Joshua Goldstein, MD, PhD
Professor of Emergency Medicine
Harvard Medical School, Massachusetts General Hospital
Boston, MA
Jerrold H. Levy, MD, FAHA, FCCM
Professor of Anesthesiology, Critical Care,
Surgery (Cardiothoracic)
Duke University School of Medicine
Durham, North Carolina
Deborah Siegal, MD, MSc, FRCPC
Hematologist (Thrombosis), The Ottawa Hospital
Tier 2 Canada Research Chair in Anticoagulant Management of Cardiovascular Disease
Associate Professor, University of Ottawa
Scientist, Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Faculty Disclosures
Dr. Burnett is a speaker for BMS/Pfizer Alliance.
Dr. Fang has no relevant financial relationships to disclose.
Dr. Goldstein is a consultant for Astrazeneca, Cayuga, CSL Behring, Octapharma, Prothya and Takeda.
Dr. Levy is a consultant for Grifols, Octopharma, Takeda and Wefen.
Dr. Siegal is a speaker for Astrazeneca, Roche and Servier.
Accredited Provider Disclosures
The following planning committee members from Boston University Chobanian & Avedisian School of Medicine’s Center for Continuing Education have no relevant financial relationships to disclose: Deborah Whalen, APRN, Boston University’s CNE Course Director and Michael Burk, BS, Operations Manager.
Planners’ and Managers’ Disclosures
Dr. Connell, activity Course Director, is a consultant for Takeda and Medzown. He is on the advisory boards for Bayer, Genentech, Sanofi and Takeda. He is a speaker for OctoPharma, Pfizer, Sanofi and Takeda and has equity in Doximity.
Mr. Fanikos is a consultant for Anthos Therapuetics, Astra-Zeneca, Pfizer and TG Therapeutics. He is also a speaker for Astra Zeneca.
Mr. Lee, Physician Assistant Accreditation Advisor, has no relevant financial relationships to disclose.
Dr. Spryopoulos is a consultant for Astra Zeneca, BMS, Janssen and Pfizer. He also receives grant research support from Astra Zeneca and Janssen.
Disclosure of Unlabeled Use
The Faculty member do plan on discussing unlabeled/investigational uses of a commercial product. Dr. Burnett will discuss stewardship over prothrombin complex concentrates when used off-label for oral FXa inhibitor reversal. Dr. Goldstein will discuss options for DOAC reversal.
Disclaimer
THIS CONTINUING EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
Accreditation Statements
In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and the Vasculearn Network. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA PRA Category 1 Credits
Boston University Chobanian & Avedisian School of Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with with the extent of their participation in the activity.
CNE Accreditation
Nursing Contact Hours: 1.75, all of which is eligible for pharmacology credit.
AAPA Accreditation
Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.75 AAPA Category 1 CME credits. Approval is valid until 10/30/2025. Pas should only claim credit commensurate with the extent of their participation.
APCE Designation Statement
This activity is approved for 1.75 CPE credit(s) under the ACPE universal activity number JA0000185-9999-24-035-H01-P. The activity is available for credit claiming through 60 days post your completion of this activity.
Available Credit
- 1.75 ACPE Pharmacy
- 1.75 Participation